Unique ID issued by UMIN | UMIN000023244 |
---|---|
Receipt number | R000026781 |
Scientific Title | investigator initiated study of Rhododenol-induced Leukoderma |
Date of disclosure of the study information | 2016/08/05 |
Last modified on | 2018/10/18 09:16:49 |
investigator initiated study of Rhododenol-induced Leukoderma
Rhodo10
investigator initiated study of Rhododenol-induced Leukoderma
Rhodo10
Japan |
Rhododenol-induced Leukoderma
Dermatology |
Others
NO
Exploratory study for the efficacy and safety of Bimatoprost in Rhododenol-induced Leukoderma.
Safety,Efficacy
Exploratory
Degree of pigmentation after six months application of Bimatoprost on target region
1.The difference of six months from baseline as for,
1)Physician's evaluations on target region
2)Colorimeter values
3)Leukoderma sizes
2.Comparison between treated area and control area.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Self control
1
Treatment
Medicine |
Bimatoprost would be applied on the target region once a day before bed time.
The dose increase would be considered to twice a day (morning after cleansing and before bed time) after three months application
20 | years-old | <= |
Not applicable |
Male and Female
1)Patients diagnosed as Rhododenol-induced Leukoderma according to diagnostic criteria of Japanese Dermatology Association (meeting all contents of essential diagnostic criteria and meeting at least one content of minor diagnostic criteria)
a)essential diagnostic criteria
i)Used Rhododenol containing cosmetics
ii)Not having Leukoderma before using Rhododenol containing cosmetics. Complete or incomplete depigmented area emerged after use of Rhododenol containing cosmetics on mostly Rhododenol applied area.
b)Minor diagnostic criteria
i)The enlargement of Leukoderma stopped within a month after withdrawal of Rhododenol containing cosmetics.
ii)After withdrawal of Rhododenol containing cosmetics, at least part of Leukoderma became re-pigmented.
2)All participants are fully explained about the aim, content and expected side effects of the study. After confirming the participants' understanding, written informed consent is taken under their free will.
1)Age under twenty years old at the time of informed consent.
2)Those who were suspected of concomitant vitiligo vulgaris.
3)Those who show skin problems such as erythema at the site of target region.
4)Those who show allagic reaction against Bimatoprost.
5)Those women who are pregnant or possibly pregnant or during lactation or those who cannot agree with contraception during the study.
6)Those otherwise principal physician considered unsuitable to include in this study.
10
1st name | |
Middle name | |
Last name | Shinichi Watanabe |
Teikyo University School of Medicine
Department of Dermatology
2-11-1 Kaga, Itabashi-ku, Tokyo 173-8601, Japan
03-3964-1211(32609)
watanabe@med.teikyo-u.ac.jp
1st name | |
Middle name | |
Last name | Shinichi Watanabe |
Teikyo University School of Medicine
Department of Dermatology
2-11-1 Kaga, Itabashi-ku, Tokyo 173-8601, Japan
03-3964-1211(32609)
watanabe@med.teikyo-u.ac.jp
Teikyo University School of Medicine
Kanebo Cosmetics Inc
Profit organization
NO
帝京大学医学部附属病院
2016 | Year | 08 | Month | 05 | Day |
Unpublished
Completed
2016 | Year | 06 | Month | 21 | Day |
2016 | Year | 08 | Month | 05 | Day |
2016 | Year | 07 | Month | 20 | Day |
2018 | Year | 10 | Month | 18 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026781